Cadila Healthcare is currently trading at Rs. 345.65, up by 1.95 points or 0.57% from its previous closing of Rs. 343.70 on the BSE.
The scrip opened at Rs. 344.30 and has touched a high and low of Rs. 347.40 and Rs. 342.50 respectively. So far 24926 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 432.40 on 10-Sep-2018 and a 52 week low of Rs. 306.35 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 352.30 and Rs. 328.55 respectively. The current market cap of the company is Rs. 35436.85 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.33% and 7.88% respectively.
Zydus Cadila has received tentative approval from the United States Food & Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets (US RLD- Myrbetriq Extended-Release Tablets), 25 mg and 50 mg.
Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder (OAB), a chronic condition of the lower urinary tract characterized by symptoms of urinary urgency, with or without urge incontinence. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
The group now has 259 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
